Latest news for Crown Equity Holdings (OTC:CRWE) Stock

Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States. It provides various consulting services to companies and individuals dealing with corporate structure and operations globally. The company also provides public relations advertising and news dissemination for public and privately held companies. Geographically, activities function throughout the region of the United States.

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ACRS

CRWE

IVFH

Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

CROWN EQUITY HLDGS INC by Crown Equity Holdings, Inc.

Crown Equity Holdings Inc

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">BranchOut Food</h3>
<ul>
<li>The Trade: BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) Director Byron Riche Jones <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 41,755 shares at</a> an average price of $0.99. To acquire these shares, it cost around $41,337.</li>
<li>What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.</li>
<li>What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.</li>
</ul>
<h3 class="wp-block-heading">Innovative Food Holdings</h3>
<ul>
<li>The Trade: Innovative Food Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVFH#OTC">IVFH</a>) Director Denver Johnson Smith <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 350,000 shares at</a> an average price of $1.20. To acquire these shares, it cost around $420,000.</li>
<li>What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.</li>
<li>What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.</li>
</ul>
<h3 class="wp-block-heading">Crown Equity Holdings</h3>
<ul>
<li>The Trade: Crown Equity Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRWE#OTC">CRWE</a>) Marketing/Merger/Acq. Officer Jamie Hadfield <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $0.25. The insider spent around $1,250 to buy those shares. </li>
<li>What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic &amp; Science Officer.</li>
<li>What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.</li>
</ul>
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">acquired a total of 154,722 shares</a> at an average price of $1.31. The insider spent around $201,808 to buy those shares.</li>
<li>What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

Crown Equity Holdings appoints Ahmad Moradi as new chairman of board

Press Releases

Crown Equity Holdings, Inc. Announces Cancellation of Letter of Intent With Level Finish LLC

Crown Equity Holdings, Inc. Files Registration Statement on Form S-1 for Proposed Public Offering of its Common Stock

Crown Equity Holdings, Inc. Announces New Chairman of Board

Management

CORRECTION BY SOURCE: Crown Equity Holdings Inc. Announces New Chairman of the Board

NWBO

Crown Equity Holdings

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.



Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.



<h3 class="wp-block-heading">BranchOut Food</h3>



<ul>
<li>The Trade: BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) Director Byron Riche Jones <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 41,755 shares at</a> an average price of $0.99. To acquire these shares, it cost around $41,337.</li>



<li>What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.</li>



<li>What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.</li>
</ul>



<h3 class="wp-block-heading">Innovative Food Holdings</h3>



<ul>
<li>The Trade: Innovative Food Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVFH#OTC">IVFH</a>) Director Denver Johnson Smith <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 350,000 shares at</a> an average price of $1.20. To acquire these shares, it cost around $420,000.</li>



<li>What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.</li>



<li>What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.</li>
</ul>



<h3 class="wp-block-heading">Crown Equity Holdings</h3>



<ul>
<li>The Trade: Crown Equity Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRWE#OTC">CRWE</a>) Marketing/Merger/Acq. Officer Jamie Hadfield <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $0.25. The insider spent around $1,250 to buy those shares. </li>



<li>What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic &amp; Science Officer.</li>



<li>What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.</li>
</ul>



<h3 class="wp-block-heading">Aclaris Therapeutics</h3>



<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">acquired a total of 154,722 shares</a> at an average price of $1.31. The insider spent around $201,808 to buy those shares.</li>



<li>What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.</li>



<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>



Read More: 



<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Crown Equity Holdings

News

Latest news for Crown Equity Holdings (OTC:CRWE) Stock

Tuesday, July 23, 2024